www.hiv-druginteractions.org



Corticosteroid Treatment Selector

Charts revised November 2017. Full information available at www.hiv-druginteractions.org

For personal use only. Not for distribution.

		ATV/r	DRV/r	LPV/r	EFV	ETV	NVP	RPV	MVC	DTG	RAL	ABC	FTC	3TC	TDF	ZDV	E/C/F/TAF	E/C/F/TDF
	Beclometasone	↑ª	↓b	↑ª	\leftrightarrow	↑ª	↑ª											
led	Budesonide	↑°	↑°	↑°	↓	1	1	\leftrightarrow	↑°	↑°								
Inhaled	Fluticasone	↑°	↑°	↑°	↓	1	↓	\leftrightarrow	↑°	↑°								
	Mometasone	↑°	↑°	↑°	↓	1	1		\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow		+	\leftrightarrow	↑°	↑°
	Clobetasol	↑ ^{c,d}	↑ ^{c,d}	↑ ^{c,d}	\leftrightarrow	↑ ^{c,d}	↑ ^{c,d}											
Topical	Fluocinolone	↑ ^{c,d}	↑ ^{c,d}	↑ ^{c,d}	\leftrightarrow	↑ ^{c,d}	↑ ^{c,d}											
ľ	Hydrocortisone (topical)	\leftrightarrow	\leftrightarrow		\leftrightarrow	\leftrightarrow	\leftrightarrow		\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow	\leftrightarrow		+	\leftrightarrow	\leftrightarrow	\leftrightarrow
	Betamethasone	↑°	↑°	↑°	↓	1	↓	₩	₩	\leftrightarrow	↑°	↑°						
	Dexamethasone	↑°↓	↑°↓	↑°↓	↓ ↓	↓ ₩	↓ ↓	₩	↓	\leftrightarrow	↑°₩	↑°↓						
er	Hydrocortisone (oral)	↑°	↑°	↑°	↓	1	1	\leftrightarrow	↑°	↑°								
Other	Methylprednisolone	↑°	↑°	↑°	↓	1	1	\leftrightarrow	↑°	↑°								
	Prednisolone	↑°	↑°	↑°	↓40%	1	1	\leftrightarrow	↑°	↑°								
	Prednisone	↑°	↑°	↑°	↓40%	1	1	\leftrightarrow	↑°	↑°								
	Triamcinolone	↑°	↑°	↑°	↓	1	\	\leftrightarrow	↑°	↑°								

Colour Legend

	No clinically significant interaction expected.
	These drugs should not be coadministered.
	Potential interaction which may require a dosage adjustment or close monitoring.
	Potential interaction predicted to be of weak intensity. No a priori dosage adjustment is recommended

Text Legend

- Potential increased exposure of the corticosteroid
- Potential decreased exposure of the corticosteroid
- $\$ Potential decreased exposure of HIV drug

No significant effect

Numbers refer to increased or decreased AUC of the corticosteroid as observed in drug-drug interaction studies.

- Coadministration of ritonavir (100 mg twice daily) increased the concentrations of the active metabolite (beclometasone-17-monopropionate) but no significant effect on adrenal function was seen. Caution is still warranted, use the lowest possible corticosteroid dose and monitor for corticosteroid side effects.
- DRV/r decreased the exposure of active metabolite (beclometasone-17-monopropionate) but no significant effect on adrenal function was seen.
- Risk of elevated corticosteroid levels, Cushing's syndrome and adrenal suppression. This risk is present for oral and injected administration, and also for topical, inhaled or eye drops
- The extent of percutaneous absorption is determined by many factors such as degree of inflammation and alteration of the skin, duration, frequency and surface of application, and use of occlusive dressings.